[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"infusion-of-ketamine-in-severe-borderline-personality-disorder\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:infusion-of-ketamine-in-severe-borderline-personality-disorder":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":30,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":36,"startDateStruct":39,"completionDateStruct":41,"leadSponsor":43,"locationsCount":5},"100600595","phase-2-ketamine-infusion-for-symptomatic-improvement-in-severe-borderline-personality-disorder-100600595",false,"NCT07099534","Ketamine Infusion for Symptomatic Improvement in Severe Borderline Personality Disorder","Ketamine Infusion for Symptomatic Improvement in Severe Borderline Personality Disorder: A Pilot Study","BorderKET","Inclusion Criteria:\n\n* Adult patient aged 18 to 65 years\n* Fluent in French\n* Person affiliated with or receiving social security benefits.\n* Diagnosis of borderline personality disorder established according to the DSM-5 MINI criteria (5 out of 9 criteria)\n* Severe borderline personality disorder\n* Patient receiving stable pharmacological (antipsychotic, mood stabilizer, antidepressant) and\u002For non-pharmacological (schema therapy, DBT) treatment for four weeks\n\nExclusion Criteria:\n\n* Personal history of an acute psychotic episode or chronic psychotic disorder\n* Personal history of a manic or hypomanic episode\n* Family history (first-degree relatives) of a psychotic disorder\n* Current severe depressive episode\n* Recreational ketamine use (multi-weekly ketamine use)\n* New long-term treatment introduced within the previous four weeks (antidepressant, antipsychotic, mood stabilizer)\n* Prescription of an Monoamine oxidase inhibitors (increased risk of hypertension)\n* Specific absolute contraindication to ketamine\n* History of cirrhosis or major liver function test abnormalities\n* Major ECG abnormality","ALL","18 Years","65 Years",{"count":21,"type":22},38,"ESTIMATED","INTERVENTIONAL",[25],"PHASE2","The main objective of this pilot study is to evaluate at D9 the evolution of BPD symptoms' intensity(scale BSL-23) in severe BPD patients, after two Ketamine infusions (0.5mg\u002Fkg at H0 and H24). The intervention is combined with the first level standard of care : Good Psychiatric Management (GPM). Patients are followed up to 3 months by regular visits conducted by a psychiatrist. Secondary outcomes are monitored including BPD symptoms at different times, suicidal ideation, depressiv symptoms, healthcare use and adverse effects.",[28,29],"Infusion of Ketamine in Severe Borderline Personality Disorder","Borderline Personality Disorder (BPD)",[31,32,33],"Ketamine","borderline personality disorder","BDP","NOT_YET_RECRUITING","2026-05-07",{"date":37,"type":38},"2026-05-12","ACTUAL",{"date":40,"type":22},"2026-09-01",{"date":42,"type":22},"2028-09-30",{"name":44,"class":45},"University Hospital, Toulouse","OTHER"]